Data completeness
2/8 — Basic
Priority Review
LOPINAVIR AND RITONAVIR by Cipla is fixed-dose combination of hiv-1 antiviral drugs lopinavir [see microbiology ()] and ritonavir. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection in adults, older).
Drug data last refreshed 21h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lopinavir and ritonavir is a fixed-dose combination of two HIV-1 protease inhibitors, where ritonavir acts as a pharmacokinetic booster to increase lopinavir plasma levels via CYP3A inhibition. It is indicated for combination antiretroviral therapy in HIV-1 infected adults and is administered orally in pellet form.
Pre-Launch
As a pre-launch product, immediate opportunity exists for launch-phase roles in regulatory affairs, commercial operations, and market access teams at Cipla's HIV franchise.
Mechanism of Action
fixed-dose combination of HIV-1 antiviral drugs lopinavir [see Microbiology ()] and ritonavir. As co-formulated in lopinavir and ritonavir tablets, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
Worked on LOPINAVIR AND RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.